Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic Covid-19 in 2020 and 2021 Publisher Pubmed

Summary: New study finds 6.2% of people with COVID-19 exhibit long-term symptoms like fatigue, cognitive issues, and respiratory problems. More prevalent in women. #LongCOVID #PublicHealth

Vos T1, 63 ; Hanson SW1 ; Abbafati C2 ; Aerts JG3 ; Alaly Z4, 5 ; Ashbaugh C1 ; Ballouz T6 ; Blyuss O7, 8 ; Bobkova P9 ; Bonsel G10 ; Borzakova S11, 12 ; Buonsenso D13, 14 ; Butnaru D15 ; Carter A1 Show All Authors
Authors
  1. Vos T1, 63
  2. Hanson SW1
  3. Abbafati C2
  4. Aerts JG3
  5. Alaly Z4, 5
  6. Ashbaugh C1
  7. Ballouz T6
  8. Blyuss O7, 8
  9. Bobkova P9
  10. Bonsel G10
  11. Borzakova S11, 12
  12. Buonsenso D13, 14
  13. Butnaru D15
  14. Carter A1
  15. Chu H16
  16. De Rose C13
  17. Diab MM17, 18
  18. Ekbom E19
  19. Tantawi ME20
  20. Fomin V21
  21. Frithiof R22
  22. Gamirova A23
  23. Glybochko PV24
  24. Haagsma JA25
  25. Haghjooy Javanmard S26
  26. Hamilton EB1
  27. Harris G27
  28. Heijenbrokkal MH28, 29
  29. Helbok R30
  30. Hellemons ME3
  31. Hillus D31
  32. Huijts SM32
  33. Hultstrom M22, 33
  34. Jassat W34
  35. Kurth F35, 36
  36. Larsson IM22
  37. Lipcsey M22
  38. Liu C37
  39. Loflin CD27
  40. Malinovschi A38
  41. Mao W17, 39
  42. Mazankova L40
  43. Mcculloch D16
  44. Menges D6
  45. Mohammadifard N42
  46. Munblit D8, 43
  47. Nekliudov NA23
  48. Ogbuoji O39
  49. Osmanov IM11, 44
  50. Penalvo JL45, 46
  51. Petersen MS47, 48
  52. Puhan MA6, 49
  53. Rahman M50
  54. Rass V30
  55. Reinig N1
  56. Ribbers GM28
  57. Ricchiuto A51
  58. Rubertsson S22, 52
  59. Samitova E40, 44
  60. Sarrafzadegan N42, 53
  61. Shikhaleva A9
  62. Simpson KE1
  63. Sinatti D13
  64. Soriano JB54, 55
  65. Spiridonova E23
  66. Steinbeis F31
  67. Svistunov AA24
  68. Valentini P13
  69. Van De Water BJ56, 57
  70. Van Den Bergemons R28
  71. Wallin E22
  72. Witzenrath M35, 58
  73. Wu Y1
  74. Xu H59
  75. Zoller T31
  76. Adolph C60, 61
  77. Albright J1
  78. Amlag JO1
  79. Aravkin AY1, 62, 63
  80. Bangjensen BL1
  81. Bisignano C1
  82. Castellano R1
  83. Castro E1
  84. Chakrabarti S1, 64
  85. Collins JK1
  86. Dai X1, 63
  87. Daoud F1
  88. Dapper C1
  89. Deen A1
  90. Duncan BB65
  91. Erickson M1
  92. Ewald SB1
  93. Ferrari AJ1, 66
  94. Flaxman AD1, 63
  95. Fullman N1
  96. Gamkrelidze A67
  97. Giles JR1
  98. Guo G1
  99. Hay SI1, 63
  100. He J1
  101. Helak M1
  102. Hulland EN1, 64
  103. Kereselidze M67
  104. Krohn KJ1
  105. Lazzaratwood A1
  106. Lindstrom A66, 68
  107. Lozano R1, 63
  108. Malta DC69
  109. Mansson J1
  110. Mantilla Herrera AM66, 70
  111. Mokdad AH1, 63
  112. Monasta L71
  113. Nomura S72, 73
  114. Pasovic M1
  115. Pigott DM1, 63
  116. Reinke G1
  117. Ribeiro ALP74, 75
  118. Santomauro DF1, 66, 76
  119. Sholokhov A1
  120. Spurlock EE1, 77
  121. Walcott R78
  122. Walker A1
  123. Wiysonge CS79, 80
  124. Zheng P1, 63
  125. Bettger JP41
  126. Murray CJL1, 63

Source: JAMA Published:2022


Abstract

Importance: Some individuals experience persistent symptoms after initial symptomatic SARS-CoV-2 infection (often referred to as Long COVID). Objective: To estimate the proportion of males and females with COVID-19, younger or older than 20 years of age, who had Long COVID symptoms in 2020 and 2021 and their Long COVID symptom duration. Design, Setting, and Participants: Bayesian meta-regression and pooling of 54 studies and 2 medical record databases with data for 1.2 million individuals (from 22 countries) who had symptomatic SARS-CoV-2 infection. Of the 54 studies, 44 were published and 10 were collaborating cohorts (conducted in Austria, the Faroe Islands, Germany, Iran, Italy, the Netherlands, Russia, Sweden, Switzerland, and the US). The participant data were derived from the 44 published studies (10501 hospitalized individuals and 42891 nonhospitalized individuals), the 10 collaborating cohort studies (10526 and 1906), and the 2 US electronic medical record databases (250928 and 846046). Data collection spanned March 2020 to January 2022. Exposures: Symptomatic SARS-CoV-2 infection. Main Outcomes and Measures: Proportion of individuals with at least 1 of the 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after SARS-CoV-2 infection in 2020 and 2021, estimated separately for hospitalized and nonhospitalized individuals aged 20 years or older by sex and for both sexes of nonhospitalized individuals younger than 20 years of age. Results: A total of 1.2 million individuals who had symptomatic SARS-CoV-2 infection were included (mean age, 4-66 years; males, 26%-88%). In the modeled estimates, 6.2% (95% uncertainty interval [UI], 2.4%-13.3%) of individuals who had symptomatic SARS-CoV-2 infection experienced at least 1 of the 3 Long COVID symptom clusters in 2020 and 2021, including 3.2% (95% UI, 0.6%-10.0%) for persistent fatigue with bodily pain or mood swings, 3.7% (95% UI, 0.9%-9.6%) for ongoing respiratory problems, and 2.2% (95% UI, 0.3%-7.6%) for cognitive problems after adjusting for health status before COVID-19, comprising an estimated 51.0% (95% UI, 16.9%-92.4%), 60.4% (95% UI, 18.9%-89.1%), and 35.4% (95% UI, 9.4%-75.1%), respectively, of Long COVID cases. The Long COVID symptom clusters were more common in women aged 20 years or older (10.6% [95% UI, 4.3%-22.2%]) 3 months after symptomatic SARS-CoV-2 infection than in men aged 20 years or older (5.4% [95% UI, 2.2%-11.7%]). Both sexes younger than 20 years of age were estimated to be affected in 2.8% (95% UI, 0.9%-7.0%) of symptomatic SARS-CoV-2 infections. The estimated mean Long COVID symptom cluster duration was 9.0 months (95% UI, 7.0-12.0 months) among hospitalized individuals and 4.0 months (95% UI, 3.6-4.6 months) among nonhospitalized individuals. Among individuals with Long COVID symptoms 3 months after symptomatic SARS-CoV-2 infection, an estimated 15.1% (95% UI, 10.3%-21.1%) continued to experience symptoms at 12 months. Conclusions and Relevance: This study presents modeled estimates of the proportion of individuals with at least 1 of 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after symptomatic SARS-CoV-2 infection. © 2022 American Medical Association. All rights reserved.
Other Related Docs
6. Does Covid-19 Escalate Aging Process? a Possible Concern, Advanced Biomedical Research (2022)